$ADCT

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

ADC Therapeutics SA (ADCT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001771910 0001771910 2026-06-30 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

ADC Therapeutics (NYSE: ADCT) said enrollment is complete in its LOTIS-7 Phase 1b trial of ZYNLONTA (loncastuximab tesirine-lpyl) plus glofitamab (COLUMVI) for relapsed/refractory DLBCL. 100 patients were dosed at 150 µg/kg; full data are expected in Q4 2026. Prior reported ORR was 89.8% with 77.6% CR.

ADC Therapeutics (NYSE: ADCT) announced a strategic reorganization, planning to cut its global workforce by about 17% to generate annualized estimated savings of roughly $10M. The company said it is preparing for regulatory and clinical milestones, including an FDA pre-sBLA meeting in August 2026 and an sBLA submission in Q4 2026, plus full LOTIS-7 data by end-2026.

ADC Therapeutics reported topline Phase 3 LOTIS-5 results for ZYNLONTA plus rituximab in relapsed/refractory DLBCL. The combo met the primary endpoint for progression-free survival (6.1 vs 4.7 months vs R-GemOx) and showed no detrimental overall survival impact, with higher response rates (58.1% vs 45.2%) and longer complete responses. Safety differed, with more serious events and Grade 5 events in the ZYNLONTA arm. Shares fell 49.68% to $1.55 premarket.

ADC Therapeutics SA (NYSE:ADCT) shares rose 0.4% to $3.4450 on Thursday after trading between $3.46 and $3.43. Volume was about 454,455 shares, down 60% vs. average. Analysts: HC Wainwright reiterated Buy with an $8 target; RBC reiterated Outperform with $6; Weiss reiterated Sell. In May 4 earnings, the company reported EPS of -$0.21 vs -$0.19 expected and revenue of $20.85M vs $19.99M.

ADC Therapeutics (NYSE:ADCT) shares rose 0.4% to about $3.45 on Thursday, after trading between $3.46 and $3.43 prior close; volume was 454,455 shares, down 60% vs average. Analysts cited mixed views: RBC $6 target (outperform), HC Wainwright $8 (buy), Weiss sell. In May 4 results, EPS was -$0.21 vs -$0.19 expected; revenue $20.85M vs $19.99M.

ADC Therapeutics announced that ZYNLONTA, its approved drug for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has a projected peak revenue potential in the U.S. of $600 million to $1 billion. The company also presented new clinical data and outlined plans for further development, including combination therapies and studies in new indications. These initiatives aim to expand ZYNLONTA's market reach and patient population.

ADC Therapeutics SA (ADCT) is projected to report a loss of 27 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Reuters. Further details likely require logging in or creating an account on the platform where the article is hosted.

ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on March 10, 2026, at 8:30 a.m. EDT to report its fourth quarter and full-year 2025 financial results and provide operational updates. The company's stock, ADCT, was up 1.95% recently, while historically, similar earnings call announcements have led to a modest average next-day decrease of 4.5% in stock price. Investors can register in advance for the call, which will include details on financial performance for the period ended December 31, 2025, and the webcast archive will be available for 30 days.